Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
Sponsor: European and Developing Countries Clinical Trials Partnership (EDCTP)
This PHASE3 trial investigates HIV Infections and is currently completed. European and Developing Countries Clinical Trials Partnership (EDCTP) leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- French National Agency for Research on AIDS and Viral Hepatitis
- Swedish International Development Cooperation Agency (SIDA)
- The Research Council of Norway
- University of Bergen
- Université Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .